Clinical Trials Directory

Trials / Unknown

UnknownNCT01886820

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
290 (estimated)
Sponsor
Navidea Biopharmaceuticals · Industry
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

To Determine the the Efficacy and Safety of \[18F\]NAV4694 PET for Detection of Cerebral β-Amyloid When Compared With Postmortem Histopathology

Conditions

Interventions

TypeNameDescription
DRUG[18F]NAV4694

Timeline

Start date
2013-06-01
Primary completion
2018-06-01
Completion
2018-09-01
First posted
2013-06-26
Last updated
2017-07-26

Locations

15 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01886820. Inclusion in this directory is not an endorsement.